Preferred Name |
pravastatin sodium |
Synonyms |
PRAV |
Definitions |
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29375" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29375" NCI Thesaurus) |
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000424450 |
altLabel |
PRAV Pravachol |
CAS Registry |
81131-70-6 |
Component of | |
cui |
C0700763 C0085542 C0700474 |
DATE FIRST PUBLISHED |
2005-03-24 |
Date last modified |
2017-12-13 |
definition |
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. In addition, pravastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cells; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29375" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29375" NCI Thesaurus) |
LT |
TRD |
NCI ID |
C29375 |
notation |
CDR0000424450 |
ORIG STY |
Drug/agent |
prefLabel |
pravastatin sodium |
tui |
T109 T121 |